ADA and glioblastoma: Overall, the markers of temozolomide resistance of ADA cell cultures that were identified in recurrent glioblastoma specimens suggest to reflect the cells’ adaptive response to the drug, indicating the acquisition of new mechanisms to evade its toxicity.